Asset Details
Do you wish to reserve the book?
Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
Do you wish to request the book?
Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
2020
Overview
The search for non‐invasive systemic biomarkers of response to PD‐L1/PD‐1 blockade immunotherapy is currently a priority in oncoimmunology. In contrast to classical tumor biomarkers, the identification of clinically useful immunological biomarkers is certainly a challenge, as anti‐cancer immune responses depend on the coordinated action of many cell types. Studies on the dynamics of systemic CD8 T‐cell populations have provided indications that such biomarkers may have a place in clinical practice. However, the power of CD8 T‐cell subsets to discriminate clinical responses in immunotherapy has so far proven to be limited. The systemic evaluation of CD8 T‐cell regulators such as myeloid cells and CD4 T cells may provide the solution. Here we discuss the value of systemic quantification of CD4 T‐cell subsets for patient selection in light of the results obtained by Prof. Kagamu′s and our team. Our studies have independently demonstrated that the evaluation of the pre‐treatment status of systemic CD4 immunity is a critical factor for the clinical outcome of PD‐L1/PD‐1 blockade therapy with robust predictive capacities.
Graphical Abstract
In this Commentary, D. Escors
et al
discuss the exciting possibility of using systemic CD4 immunity pre‐treatment status as a predictive tool of clinical outcome following PD‐L1/PD‐1 blockade cancer immunotherapy.
